JP2020506946A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506946A5
JP2020506946A5 JP2019542502A JP2019542502A JP2020506946A5 JP 2020506946 A5 JP2020506946 A5 JP 2020506946A5 JP 2019542502 A JP2019542502 A JP 2019542502A JP 2019542502 A JP2019542502 A JP 2019542502A JP 2020506946 A5 JP2020506946 A5 JP 2020506946A5
Authority
JP
Japan
Prior art keywords
oxo
carboxamide
dihydropyridazine
chlorophenyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019542502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506946A (ja
JP7128826B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/052627 external-priority patent/WO2018146010A1/en
Publication of JP2020506946A publication Critical patent/JP2020506946A/ja
Publication of JP2020506946A5 publication Critical patent/JP2020506946A5/ja
Application granted granted Critical
Publication of JP7128826B2 publication Critical patent/JP7128826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019542502A 2017-02-09 2018-02-02 がん治療のための2-ヘテロアリール-3-オキソ-2,3-ジヒドロピリダジン-4-カルボキサミド類 Active JP7128826B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17155406 2017-02-09
EP17155406.6 2017-02-09
EP17202882 2017-11-21
EP17202882.1 2017-11-21
PCT/EP2018/052627 WO2018146010A1 (en) 2017-02-09 2018-02-02 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2020506946A JP2020506946A (ja) 2020-03-05
JP2020506946A5 true JP2020506946A5 (enExample) 2021-03-11
JP7128826B2 JP7128826B2 (ja) 2022-08-31

Family

ID=61188789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542502A Active JP7128826B2 (ja) 2017-02-09 2018-02-02 がん治療のための2-ヘテロアリール-3-オキソ-2,3-ジヒドロピリダジン-4-カルボキサミド類

Country Status (39)

Country Link
US (3) US12522594B2 (enExample)
EP (1) EP3580211B1 (enExample)
JP (1) JP7128826B2 (enExample)
KR (1) KR102627266B1 (enExample)
CN (3) CN116531380B (enExample)
AU (1) AU2018217860B2 (enExample)
BR (1) BR112019016497A2 (enExample)
CA (1) CA3052718A1 (enExample)
CL (1) CL2019002255A1 (enExample)
CO (1) CO2019008684A2 (enExample)
CR (1) CR20190364A (enExample)
CU (1) CU24564B1 (enExample)
CY (1) CY1124484T1 (enExample)
DK (1) DK3580211T3 (enExample)
DO (1) DOP2019000206A (enExample)
EC (1) ECSP19057713A (enExample)
ES (1) ES2847162T3 (enExample)
GE (2) GEAP202115183A (enExample)
HR (1) HRP20210143T1 (enExample)
HU (1) HUE053191T2 (enExample)
IL (1) IL268469B (enExample)
JO (1) JOP20190193B1 (enExample)
LT (1) LT3580211T (enExample)
MA (1) MA47447B1 (enExample)
MX (1) MX2019009571A (enExample)
MY (1) MY198510A (enExample)
NI (1) NI201900085A (enExample)
PE (1) PE20191496A1 (enExample)
PH (1) PH12019501846A1 (enExample)
PL (1) PL3580211T3 (enExample)
RS (1) RS61401B1 (enExample)
SA (1) SA519402422B1 (enExample)
SG (1) SG11201907232XA (enExample)
SI (1) SI3580211T1 (enExample)
TW (1) TWI770113B (enExample)
UA (1) UA124507C2 (enExample)
UY (1) UY37606A (enExample)
WO (1) WO2018146010A1 (enExample)
ZA (1) ZA201905902B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201810366WA (en) * 2016-05-25 2018-12-28 Bayer Pharma AG 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
US12522594B2 (en) 2017-02-09 2026-01-13 Deutsches Krebsforschungszentrum 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
CN112724256B (zh) * 2019-10-28 2022-09-16 中国农业大学 一种高稳定性的磺胺类药物抗体hAb 4D11及其应用
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
BR112022007837A2 (pt) 2019-12-16 2022-07-05 Bayer Ag Combinação de um inibidor de ahr e um anticorpo inibidor de pd1 e seu uso no tratamento de câncer
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ahrシグナル伝達の調節に有用なピリドピリミジン誘導体
BR112022019387A2 (pt) * 2020-03-27 2022-11-16 Dong A St Co Ltd Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos
WO2021236717A1 (en) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Fused imidazole derivatives as ahr antagonists
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN114369097B (zh) * 2020-10-15 2023-07-14 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN114539221B (zh) * 2020-11-27 2026-08-07 苏州泽璟生物制药股份有限公司 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用
CN114685426B (zh) * 2020-12-28 2026-05-26 苏州泽璟生物制药股份有限公司 磺酰胺类抑制剂及其制备方法和应用
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
WO2023043753A1 (en) * 2021-09-14 2023-03-23 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders
US20230190961A1 (en) 2021-10-20 2023-06-22 University Of Rochester Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells
CN119948035A (zh) 2022-10-03 2025-05-06 捷豹治疗有限公司 可用于调节AhR信号传导的化合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU756275B2 (en) * 1998-08-14 2003-01-09 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives
JP2000119257A (ja) * 1998-08-14 2000-04-25 Nippon Nohyaku Co Ltd ピリダジノン誘導体
US6358964B1 (en) 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
JP4233868B2 (ja) 2000-09-18 2009-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリダジノンおよびトリアジノン化合物類ならびにそれらの医薬用途
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
DE102004055998A1 (de) 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
CA2586420A1 (en) 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
WO2006082952A1 (ja) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited アミド化合物
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
AR057986A1 (es) 2005-11-21 2008-01-09 Japan Tobacco Inc Compuesto heterociclico y su uso farmaceutico
EP2023910B1 (en) 2006-05-03 2013-06-19 Symrise AG Ah receptor antagonists
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
DE102006054205A1 (de) 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
US20100210649A1 (en) * 2006-12-21 2010-08-19 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CA2741666C (en) 2008-10-31 2017-04-11 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US20130338201A1 (en) 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
US10314810B2 (en) 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2015143164A1 (en) 2014-03-19 2015-09-24 President And Fellows Of Harvard College Antimicrobial agents and screening methods
SG11201810366WA (en) 2016-05-25 2018-12-28 Bayer Pharma AG 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
US12522594B2 (en) 2017-02-09 2026-01-13 Deutsches Krebsforschungszentrum 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
EP3713926B1 (en) 2017-11-21 2023-06-07 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
EP3713931B1 (en) 2017-11-21 2025-03-05 Deutsches Krebsforschungszentrum 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
WO2019101642A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
US11524944B2 (en) 2017-11-21 2022-12-13 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as AHR inhibitors
CN113015526A (zh) 2018-09-19 2021-06-22 豪夫迈·罗氏有限公司 螺环2,3-二氢-7-氮杂吲哚化合物及其用途
EP3880198A4 (en) 2018-11-14 2022-08-10 The Broad Institute, Inc. ARYHYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS
EP4013508A1 (en) 2019-08-12 2022-06-22 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
WO2021074279A1 (en) 2019-10-16 2021-04-22 Bayer Aktiengesellschaft Spiro-fused tricyclic map4k1 inhibitors
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
WO2022167627A1 (en) 2021-02-05 2022-08-11 Bayer Aktiengesellschaft Map4k1 inhibitors

Similar Documents

Publication Publication Date Title
HRP20210143T1 (hr) 2-heteroaril-3-okso-2,3-dihidropiridazin-4-karboksamidi za liječenje raka
RU2404164C2 (ru) Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
RU2497822C2 (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2017530185A5 (enExample)
JP2019537571A5 (enExample)
JP2019533694A5 (enExample)
JP2019518036A5 (enExample)
JP2016534023A5 (enExample)
JP2016528201A5 (enExample)
JP2017508763A5 (enExample)
RU2014147191A (ru) Амидопроизводные как блокаторы ttx-s
JP2017537948A5 (enExample)
JP2017511794A5 (enExample)
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
RU2004129780A (ru) Производные аминоиндазолов, способ получения и промежуточные продукты этого способа в качестве лекарственных средств и содержащие их фармацевтические композиции
RU2019133530A (ru) ПРОИЗВОДНЫЕ АМИДА В КАЧЕСТВЕ БЛОКАТОРОВ Nav1.7 И Nav1.8
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2018522847A5 (enExample)
JP2019532072A5 (enExample)
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
JP2015514679A5 (enExample)
RU2014147243A (ru) Производные пирролопиридинона в качестве ttx-s блокаторов
JP2021520340A5 (enExample)
JP2016534143A5 (enExample)